Screening for bladder cancer: The best opportunity to reduce mortality

Journal of the Canadian Urological Association

Volumn 3, Issue 6 SUPPL. 4, 2009, Pages

  Fradet, Yves ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 75849120090     PISSN: 19116470     EISSN: 19116470     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Nieder AM, Lotan Y, Nuss GR, et al. Are patients with hematuria appropriately referred to Urology? A multi-institutional questionnaire based survey. 2009. In Press.
2. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
3. Silverman DT, Hartge P, Morrison AS, et al. Epidemiology of bladder cancer. Hematol Oncol Clin North Am 1992;6:1-30.
4. Vaidya A, Soloway M, Hawke C, et al. De novo muscle invasive bladder cancer: is there a change in trend? J Urol 2001;165:47-50. discussion 50.
5. Marshall VF. Current clinical problems regarding bladder tumors. Cancer 1956;9:543-50.
6. Ressequie LJ, Nobrega FT, Farrow GM, et al. Epidemiology of renal and ureteral cancer in Rochester, Minnesota, 1950-1974, with special reference to clinical and pathologic features. Mayo Clin Proc. 1978;53:503-10.
7. Messing EM, Young TB, Hunt VB, et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 1995;45:387-96; discussion 396-7.
8. Messing EM, Madeb R, Young T, et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 2006;107:2173-79.
9. Britton JP, Dowell AC, Whelan P, et al. A community study of bladder cancer screening by the detection of occult urinary bleeding. J Urol 1992;148:788-90.
10. Mayfield MP, Whelan P. Bladder tumours detected on screening: results at 7 years. Br J Urol 1998;82: 825-8.
11. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and metaanalyses. Urology 2003;61:109-18.
12. Raitanen MP, Aine R, Rintala E, et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol 2002;41: 284-89.
13. Nabi G, Greene DR, O'Donnell M. How important is urinary cytology in the diagnosis of urological malignancies? Eur Urol 2003;43:632-6.
14. Lodde M, Fradet Y. The detection of genetic markers of bladder cancer in urine and serum. Curr Opin Urol 2008;18:499-503.
15. TM in the detection of recurrent urothelial carcinoma. An update on 1991 analyses. Cancer (Cancer Cytopathol) 2006;108:60-5.
16. Lodde M, Mian C, Wiener H, et al. Detection of upper urinary tract transitional cell carcinoma with ImmunoCyt: a preliminary report. Urology 2001;58:362-6.
17. TM, and urine cytology in detection of recurrent urothelial carcinoma: a "split-sample" study. Cancer (Cancer Cytology) 2009. In press.
18. Schmitz-Dräger BJ, Beiche B, Tirsar LA, et al. Immunocytology in the assessment of patients with asymptomatic microhaematuria. Eur Urol 2007;51:1582-8.
19. Hemstreet III GP, Yin S, Ma Z, et al. Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine. J Natl Cancer Inst 2001;93:427-36.
20. Moore LE, Pfeiffer RM, Poscablo C, et al. Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. The Lancet Oncol 2008:9:359-66.
21. Urologic Diseases in America 2007. Editors MS Litwin, CS Saigal. National Institute of Diabetes and Digestive and Kidney Diseases.
22. Botteman MF, Pashos CL, Redaelli A, et al. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003;21:1315-30.
23. Lotan Y, Svatek RS, Sagalowsky AI. Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis. Cancer 2006;107:982-90.
24. Fradet Y, Grossman HB, Gomella L, et al. A comparison of hemaminolevulinate (HKL) fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer. J Urol 2007;178:68-73.